Summarized by Masters of Longevity from PR Newswire.
Company investor presentation outlines a 2027 growth plan linking AI-driven manufacturing with regenerative medicine supply chain expansion and commercial partnerships.
Key Takeaways
- MetaTech AP reported NT$1.391 billion revenue for the first nine months of 2026, up 21% year over year.
- MetaTech AP will manufacture human platelet lysate while Zheng Yang Biomedical handles global sales and marketing under their collaboration.
- MetaTech AP and subsidiary Locus Cell are building AI-driven iCDMO capabilities and preparing local cell therapy manufacturing and clinical development programs.
